SARS-CoV-IN-5

• UNSPSC Description:

  SARS-CoV-IN-5 (compound 49) is a highly selective, nonpeptidic and noncovalent 3CLpro inhibitor with IC50s of 38 nM, 21.1 nM and 86 nM for 3CLpro of SARS-CoV-1, SARS-CoV-2, Bat coronavirus WIV1, respectively. SARS-CoV-IN-5 inhibits the replication of the SARS-CoV-2 delta variant with an EC50 of 0.272 μM. SARS-CoV-IN-5 significantly reduces the lung viral copies in a K18-hACE2 transgenic mouse model. SARS-CoV-IN-5 has good target-specific and potential broad-spectrum anticoronavirus activities against SARS-CoV-1, WIV1, MERS, HCoV-OC43, HCoV-229E, and HKU9[1].

• Target Antigen:

  SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/sars-cov-in-5.html

• Smiles:

  O=C(N1CCN(C)CC1)C2=CC(Br)=CC([N+]([O-])=O)=C2N[C@H]3[C@H](CCCC3)NC(C(C4=CC=CC(F)=C4N5)=CC5=O)=O

• Molecular Weight:

  629.48

• References & Citations:

  [1]Zhidong Jiang, et al. Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CL^pro Inhibitors as anti-SARS-CoV-2 Drug Candidate. J Med Chem. 2024 Aug 8;67(15):12760-12783.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported